Eyenuk Will Announce Results From Prospective, Multi-Center, Pivotal Clinical Trial on the EyeArt® AI Eye Screening System at ARVO ConferenceApril 25, 2019
Artificial Intelligence (AI) Technology Developed To Make In-Clinic,
Real-Time Diabetic Retinopathy Screening Possible for Any Physician
LOS ANGELES–(BUSINESS WIRE)–Eyenuk
Inc., a global artificial intelligence (AI) medical technology and
services company and the leader in real-world applications for AI Eye
Screening™, announced today that it will release results from its
prospective, multi-center, pivotal clinical
trial (NCT03112005) on the EyeArt® AI Eye Screening
System for autonomous detection of diabetic retinopathy (DR) at the
Association for Research in Vision and Ophthalmology (ARVO) Imaging in
the Eye Conference this weekend in Vancouver, British Columbia.
On behalf of the 15-center study team, Jennifer Lim, MD, Marion H.
Schenk Chair in Ophthalmology and Director of Retina Service at the
University of Illinois at Chicago, will present results from the
EyeArt prospective, pivotal clinical trial “Artificial Intelligence
Screening for Diabetic Retinopathy: Analysis From a Pivotal
Multi-Center Prospective Clinical Trial.” The presentation will be
part of the 2019 ARVO Imaging in the Eye Conference at 5:15 p.m. PDT
on Saturday, April 27, 2019, in the Vancouver Convention Centre (East)
Ballroom A and B.
In addition, the clinical team from the Washington University School
of Medicine (St. Louis) will present results from its independent
clinical study involving the EyeArt® AI Eye Screening
System in real-world clinical applications:
“Cost-Effectiveness of Primary Care-Based Non-Mydriatic Fundus
Photography with Automated Retinal Image Analysis Screening Among
Low-Income Patients with Diabetes,” which will be presented at 11
a.m. PDT on Wednesday, May 1, 2019, in the Vancouver Convention
Centre (West) Room 220.
“Diabetic Retinopathy Screening in a Primary Care Setting Using
Non-Mydriatic Photography and Automated Retinal Image Analysis
Improves Compliance with Follow-Up Ophthalmic Care,” which will be
Poster B0005 at 3 p.m. PDT on Wednesday, May 1, 2019, in the
Vancouver Convention Centre West Exhibition Hall.
- “Cost-Effectiveness of Primary Care-Based Non-Mydriatic Fundus
Eyenuk will showcase its EyeArt® AI Eye Screening System for
autonomous detection of DR at Booth #1637 at the Vancouver Convention
Centre Exhibition Hall. In addition, key management team members will be
available to meet with researchers, clinicians and potential industry
partners during the ARVO annual meeting.
About the EyeArt® AI Eye Screening System
The EyeArt AI Eye Screening System is the most extensively validated AI
technology for autonomous detection of diabetic retinopathy, tested in
the real world on more than half million patient visits globally with
over two million images collected in real-world clinical environments.
The EyeArt AI Eye Screening System makes in-clinic, real-time DR
screening possible for any physician, enabling quick and accurate
identification of patients with referable DR during a diabetic patient’s
The EyeArt AI Eye Screening System was developed with funding in part
from the U.S. National Institutes of Health (NIH) and is validated by
the U.K. National Health Service (NHS). The EyeArt System has CE marking
in the European Union and a Health Canada license. In the U.S., the
EyeArt System is limited by federal law to investigational use.
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology
company and the leader in real-world AI Eye Screening™ for autonomous
disease detection and AI Predictive Biomarkers™ for risk assessment and
disease surveillance. Eyenuk is on a mission to screen every eye in the
world to ensure timely diagnosis of life- and vision-threatening
diseases, including diabetic retinopathy, glaucoma, age-related macular
degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.